Market Cap 172.20M
Revenue (ttm) 0.00
Net Income (ttm) -13.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.46
Volume 466,000
Avg Vol 924,622
Day's Range N/A - N/A
Shares Out 183.89M
Stochastic %K 22%
Beta -0.77
Analysts Strong Sell
Price Target $10.00

Company Profile

Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 pati...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 838 6436
Website: tevogen.com
Address:
15 Independence Boulevard, Suite #410, Warren, United States
1BucksFan
1BucksFan Aug. 22 at 10:45 PM
$TVGN A major milestone in Tevogen’s pursuit of accessibility was the launch of Tevogen.AI, which leverages advanced algorithms and a strategic partnership with Microsoft and Databricks to accelerate therapeutic discovery and development. Tevogen extends its gratitude to BINJE and its founder and editor, Tom Bergeron, for this recognition, and congratulates fellow honorees, including BioNJ President & CEO Debbie Hart, BioNJ members Christopher Cozic (Genmab), Joaquin Duato (Johnson & Johnson), Paul Hudson (Sanofi), and Dr. Jean-Pierre Issa (Coriell Institute for Medical Research), on being named to BINJE’s BEST Health Care 2025 list.
0 · Reply
1BucksFan
1BucksFan Aug. 22 at 10:43 PM
$TVGN Tevogen Bio is focused on developing affordable, safe, and easy-to-administer T cell therapies for acute viral infections, the long-term effects of viral infections, and both viral and non-viral induced cancers. The Company’s proprietary ExacTcell™ platform enabled a proof-of-concept clinical trial with highly positive results, published in Blood Advances. Tevogen’s business model is designed to withstand current market pressures by operating a lean, capital-efficient structure that avoids licensing overhead through full ownership of its core intellectual property. Its off-the-shelf, genetically unmodified CD8+ T cell therapies aim to reduce manufacturing complexity and cost, aligning with U.S. healthcare priorities such as affordability, domestic production, and scalable innovation. A major milestone in Tevogen’s pursuit of accessibility was the launch of Tevogen.AI, which leverages advanced algorithms and
0 · Reply
1BucksFan
1BucksFan Aug. 22 at 10:41 PM
$TVGN its recognition, BINJE noted, “Driven by an unrelenting passion to advance the cause of health equity for all and the belief that societal prosperity and business success are intrinsically linked, Saadi has tirelessly strived to pave the way for a new era in the industry, one in which access to life-saving medications is more evenly distributed through a sustainable biopharma model.”
0 · Reply
1BucksFan
1BucksFan Aug. 22 at 10:39 PM
$TVGN WARREN, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), announced today that it has been named in BINJE’s BEST Health Care 2025: Companies, Organizations and Service Providers. BINJE, a media outlet covering business and politics across New Jersey, highlighted Tevogen Bio’s Founder and CEO, Ryan Saadi, MD, MPH, for his commitment to health equity and innovation in sustainable biopharma.
1 · Reply
mscp
mscp Aug. 22 at 6:42 PM
$TVGN 6 months. By then trading in dollars
0 · Reply
chris_stocks
chris_stocks Aug. 22 at 4:05 PM
$TVGN Wow! This will be the 18th day of it being under a dollar. Getting close to when they'll do an RS, or am I wrong?
1 · Reply
LasVegas_Rocker16
LasVegas_Rocker16 Aug. 22 at 3:28 PM
$TVGN Lets Get over ^ 4.20 soon! Loading more today!!!
0 · Reply
Baxter22
Baxter22 Aug. 22 at 3:02 PM
$TVGN in 1H25 their burn was ~$16M with the majority of it going to stock-based compensation ($5M) and legal fees ($7M) meaning they have spent the most money on executive compensation and legal fees with very little going to R&D. This low burn rate is not sustainable since it is only occurring because they do not have any ongoing trials.
0 · Reply
LasVegas_Rocker16
LasVegas_Rocker16 Aug. 21 at 8:59 PM
$TVGN All the rich TVGN Executives need buy many more shares! Charts look great! This will Spike soon! This should be way above $ 4.20 by next week!
0 · Reply
Baxter22
Baxter22 Aug. 21 at 12:31 PM
$TVGN it is so strange how frequently these guys repeat PRs. I’m guessing they are trying to push the share price above $1 to avoid the delisting clock….
1 · Reply
Latest News on TVGN
Tevogen Bio Announces 2025 Annual Meeting

Apr 25, 2025, 2:33 PM EDT - 4 months ago

Tevogen Bio Announces 2025 Annual Meeting


1BucksFan
1BucksFan Aug. 22 at 10:45 PM
$TVGN A major milestone in Tevogen’s pursuit of accessibility was the launch of Tevogen.AI, which leverages advanced algorithms and a strategic partnership with Microsoft and Databricks to accelerate therapeutic discovery and development. Tevogen extends its gratitude to BINJE and its founder and editor, Tom Bergeron, for this recognition, and congratulates fellow honorees, including BioNJ President & CEO Debbie Hart, BioNJ members Christopher Cozic (Genmab), Joaquin Duato (Johnson & Johnson), Paul Hudson (Sanofi), and Dr. Jean-Pierre Issa (Coriell Institute for Medical Research), on being named to BINJE’s BEST Health Care 2025 list.
0 · Reply
1BucksFan
1BucksFan Aug. 22 at 10:43 PM
$TVGN Tevogen Bio is focused on developing affordable, safe, and easy-to-administer T cell therapies for acute viral infections, the long-term effects of viral infections, and both viral and non-viral induced cancers. The Company’s proprietary ExacTcell™ platform enabled a proof-of-concept clinical trial with highly positive results, published in Blood Advances. Tevogen’s business model is designed to withstand current market pressures by operating a lean, capital-efficient structure that avoids licensing overhead through full ownership of its core intellectual property. Its off-the-shelf, genetically unmodified CD8+ T cell therapies aim to reduce manufacturing complexity and cost, aligning with U.S. healthcare priorities such as affordability, domestic production, and scalable innovation. A major milestone in Tevogen’s pursuit of accessibility was the launch of Tevogen.AI, which leverages advanced algorithms and
0 · Reply
1BucksFan
1BucksFan Aug. 22 at 10:41 PM
$TVGN its recognition, BINJE noted, “Driven by an unrelenting passion to advance the cause of health equity for all and the belief that societal prosperity and business success are intrinsically linked, Saadi has tirelessly strived to pave the way for a new era in the industry, one in which access to life-saving medications is more evenly distributed through a sustainable biopharma model.”
0 · Reply
1BucksFan
1BucksFan Aug. 22 at 10:39 PM
$TVGN WARREN, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), announced today that it has been named in BINJE’s BEST Health Care 2025: Companies, Organizations and Service Providers. BINJE, a media outlet covering business and politics across New Jersey, highlighted Tevogen Bio’s Founder and CEO, Ryan Saadi, MD, MPH, for his commitment to health equity and innovation in sustainable biopharma.
1 · Reply
mscp
mscp Aug. 22 at 6:42 PM
$TVGN 6 months. By then trading in dollars
0 · Reply
chris_stocks
chris_stocks Aug. 22 at 4:05 PM
$TVGN Wow! This will be the 18th day of it being under a dollar. Getting close to when they'll do an RS, or am I wrong?
1 · Reply
LasVegas_Rocker16
LasVegas_Rocker16 Aug. 22 at 3:28 PM
$TVGN Lets Get over ^ 4.20 soon! Loading more today!!!
0 · Reply
Baxter22
Baxter22 Aug. 22 at 3:02 PM
$TVGN in 1H25 their burn was ~$16M with the majority of it going to stock-based compensation ($5M) and legal fees ($7M) meaning they have spent the most money on executive compensation and legal fees with very little going to R&D. This low burn rate is not sustainable since it is only occurring because they do not have any ongoing trials.
0 · Reply
LasVegas_Rocker16
LasVegas_Rocker16 Aug. 21 at 8:59 PM
$TVGN All the rich TVGN Executives need buy many more shares! Charts look great! This will Spike soon! This should be way above $ 4.20 by next week!
0 · Reply
Baxter22
Baxter22 Aug. 21 at 12:31 PM
$TVGN it is so strange how frequently these guys repeat PRs. I’m guessing they are trying to push the share price above $1 to avoid the delisting clock….
1 · Reply
Tttanya
Tttanya Aug. 21 at 1:07 AM
$TVGN lets goo
0 · Reply
robsmi63
robsmi63 Aug. 21 at 12:11 AM
$TVGN tic toc
0 · Reply
LasVegas_Rocker16
LasVegas_Rocker16 Aug. 20 at 4:09 PM
$TVGN That is great news! Let get this fired up today beforw word gets out! Still loading a load more now! Once this gets out! hit my wammy bar on my triple neck! Go all day!!! On to St Lucia! The sharks need some bait soon!
0 · Reply
CulinaryCapitalist
CulinaryCapitalist Aug. 20 at 3:43 PM
$TVGN
0 · Reply
Pharma_Stock_Calls
Pharma_Stock_Calls Aug. 20 at 2:03 PM
🚨 New Signal ✅ 💊 $TVGN 🗓️ Aug 20, 2025 🎯 Entry: $0.9307 🎯 Target: $1.0952 (+17.67%)
0 · Reply
robsmi63
robsmi63 Aug. 20 at 1:31 PM
$TVGN financed!
1 · Reply
robsmi63
robsmi63 Aug. 20 at 1:29 PM
$TVGN $50 million should bring them to Q4 2026, their timeframe to real revenue. We good. Thank goodness they got this financing. Last piece of the puzzle.
1 · Reply
Teo_j
Teo_j Aug. 20 at 6:32 AM
0 · Reply
LasVegas_Rocker16
LasVegas_Rocker16 Aug. 20 at 12:27 AM
$TVGN Loading a ton more! kidding me! below a 1.00! This should be 5.00 min! Executives need ro get moving ang get some A products ready to launch soon! Start up is over! Time too Execute ! or merge with a big company!
1 · Reply
Teo_j
Teo_j Aug. 19 at 8:03 PM
$TVGN short this scam
0 · Reply
Nchums89jt
Nchums89jt Aug. 19 at 7:47 PM
$TVGN another good news, but the price is falling. I don't know if these news are fake or
2 · Reply
jeroen2505
jeroen2505 Aug. 19 at 6:18 PM
$TVGN D. Boral Capital Maintains Buy on Tevogen Bio Holdings, Maintains $10 Price Target Expenses significantly lower with expansion on multiple efforts; Q2 2025 loss from operations reduced to $5.4 million vs $8.6 million in Q2 2024. Tevogen maximizes capital efficiency, maintains access to financing to support growth, and anticipates revenue by end of 2026; Exploring options to address limited tradable float. Building infrastructure, advancing AI, and expanding internal capabilities in a sector with limited growth
0 · Reply